Palliative care for multiple sclerosis: a counter-intuitive approach?
'Palliative and hospice care -yes, it's a great thing -for patients with cancer!' Many of you -readers of this journal -and patients or families alike will immediately link hospice and cancer. In fact, when Dame Dr Cicely Saunders founded the first modern hospice in 1967 in London, UK, St. Christopher's was also open to patients with motor neuron disease (MND)/ Amyotrophic Lateral Sclerosis (ALS). Her vision was not only academic (incorporating teaching and research), but was also inclusive for all in need -including patients with non-tumour diseases. 1 It was in line with this tradition and under the impression that non-tumour patients still do not have adequate access to such hospice or palliative care when needed that the British MS Society -as a patient organization -funded a research project the core data of which you will find in this issue. 2 This study is remarkable both in clinical and scientific terms.
Is palliative care helpful to patients with multiple sclerosis?
The setting of this study was that in an area where multiple sclerosis (MS) patients already have good access to 'traditional' structures, such as GP, neurology, rehabilitation, and social work, an additional and complementing palliative care service was offered for severely affected patients. 2 This randomized controlled study showed a significant improvement in the management of key symptoms (pain, nausea, vomiting, mouth problems, and sleeping difficulties) as well as significantly reducing caregiver burden. Furthermore, such a service is cost-effective, mainly by reducing caregiver burden and use of primary and acute hospital services. 3 Despite the obvious methodological limitations (e.g. low patient numbers, short follow-up, difficult outcome parameters for good palliative care, and no formal assessment of important issues such as assisting in end-of-life care planning), encouragingly significant results were found -both for patients and relatives! The benefit of such a service in 'real life', however, would probably be even greater than this study can prove (e.g. help with coordination of services, endof-life decisions, advance directives). Specifically, the study design -for ethical reasons -excluded all emergency interventions, in which randomization was bypassed and immediate help offered. These data therefore very much support the notion that palliative care issues are similar in all severely affected patients in the sense of a 'common pathway' and independent of the different underlying diagnoses. This is reflected in all palliative care definitions concentrating on 'needs' and not 'diagnoses'. [4] [5] [6] When should a palliative care service be requested for a patient with MS?
In this study, the palliative care service was called in when the primary caregivers thought it appropriate. 2 This will depend on the identification of unmet palliative care needs on the part of the treating physician. For patients with non-tumour diagnosis, this usually leads to overly late referrals reflecting more severe disease burden or higher mortality in non-tumour versus tumour patients on palliative care units. 6 The oncological world has started to think about 'early integration' of specialized palliative care structures, depending on the tumour entity, sometimes even at the time of diagnosis. The American Society of Clinical Oncology has recently advocated this approach, 7 and disease-specific Standard Operating Procedures defining objective 'green and red flags' are being formulated. 8 For neurological disorders, both relentlessly progressing (e.g. MND/ALS), but also more long term chronic ones such as MS, similar formalized approaches will have to be developed. Otherwise, the individual patient will depend too much on the physician recognizing -or not -unmet palliative care needs. The reported British, but also accumulating international experience with palliative care for MS patients 9 has very quickly resulted in inclusion of this concept into the Code of Good Practice which has been formulated by the European MS Platform, stating that in Europe all MS patients must have access to palliative care assessment and if necessary specialized palliative care service. 10 How does palliative care have to adapt to future challenges?
Due to epidemiological challenges and anticipated changes in causes of mortality, hospice and palliative care will have to open up more and more to nontumour patients. Whereas currently, most palliative care services care for 90-95% tumour patients, international estimations point towards a 40% nontumour population within hospice and palliative care in the future. 11 For this development, MS patients can serve as a paradigm for the chronic, non-cancer population. This study gives important hints on how to develop the necessary structures: new services must complement and collaborate with the existing ones. Only then, will acceptance grow, patient transfer will be smooth and disease-specific knowledge will be transferred to the palliative care phase. Within palliative care, sometimes there is a reluctance to admit nontumour patients, due to lack of clinical knowledge, but also due to fear of potentially being overwhelmed. 11 The current study clearly shows that -if organized well -this will not be the case, as patients in the study setting were mostly seen on a consult basis, and no more than three times. 2 It will depend very much on the quality of care of the primary neurological structures, that inclusion of palliative care at this relatively low rate will be enough to meet the patients' needs.
Is it possible to perform high-quality research in a palliative care population?
In recent years, the debate on palliative care research has moved from 'whether' to 'how' such research is possible. Introducing the palliative care approach into research protocols, however, means using patient relevant subjective inclusion criteria (need rather than disability) and subjective or composite end-points, which may at first feel uneasy both to reviewers and readers. Furthermore, when reading the relatively low numbers (26 patients in each arm), one has to consider firstly that this study population is an especially vulnerable one with high drop-out rates and further inherent obstacles to research. 12, 13 Secondly, this study is a phase II trial within the MRC framework for complex interventions, which now has to be followed up with a larger phase III trial. 14 The authors of the current study have to be congratulated for demonstrating that despite all obstacles, a randomized controlled trial also within palliative care research is feasible and can produce significant results. Many more such studies are desperately needed within palliative care to move away from needs assessment to intervention studies. Only if we achieve this, will palliative care be recognized as a self-standing and scientific field of medicine. Readers of this journal who are used to many studies using quantitative methodology, however, must be alerted to the fact that meaningful quantitative studies frequently need a qualitative methodology study first. In this case, the authors did such a study, and only then formed a meaningful new service which was suitable for their setting. 15 Not only may the service structure differ regionally, but also the research methods used. Performing a randomized controlled trial using the 'delayed intervention' approach of 12 weeks might for instance be considered unethical in other countries. Therefore, the specific conclusions drawn from this study may be somewhat limited, but the principles addressed here are of general relevance. Future studies on the issue of palliative care in MS in different or multicentre settings, using different intervention approaches, and different research protocols are eagerly awaited.
